Cough in chronic obstructive pulmonary disease: is it important and what are the effects of treatment?

Cough

Peter MA Calverley¹ 

[1] Clinical Sciences Centre, University Hospital Aintree, Lower Lane, L9, 7AL, Liverpool, United Kingdom

关键词: Treatment;    Bronchitis;    Mucus;    Chronic Obstructive Pulmonary Disease;    Cough;   

Others  :  809239
DOI  :  10.1186/1745-9974-9-17

 received in 2013-04-11, accepted in 2013-06-03,  发布年份 2013

【 摘 要 】

Over the last 40 years the assessment and treatment of chronic obstructive pulmonary disease has focused primarily on airflow obstruction with little significance given to the problem of cough. The reasons for this include a view that cough arises simply from the direct irritant and inflammatory effect of cigarette smoke or the presence of excess mucus in the airways. Doubt that cough is of any consequence to patients or responsive to current therapies has reinforced this opinion. At odds with this is the emerging evidence that cough impacts adversely on patients’ health status and forms an important component of recently validated quality of life instruments. This article presents the arguments why the assessment and treatment of cough should have a more prominent place in the clinical management of COPD.

【 授权许可】

   
2013 Calverley; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R: Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD executive summary. Am J Respir Crit Care Med 2012.
• [2]Smith J, Woodcock A: Cough and its importance in COPD. Int J Chron Obstruct Pulmon Dis 2006, 1(3):305-314.
• [3]Medical Research Council Committee on Research into Chronic Bronchitis: Instructions for the use of the questionnaire on respiratory symptoms. Devon, UK: W.J.Holman; 1966.
• [4]Doll R, Peto R, Wheatley K, Gray R, Sutherland I: Mortality in relation to smoking: 40 years' observations on male British doctors. Br Med J 1994, 309(6959):901-911.
• [5]Gamble E, Grootendorst DC, Hattotuwa K, O'Shaughnessy T, Ram FS, Qiu Y, Zhu J, Vignola AM, Kroegel C, Morell F, Pavord ID, Rabe KF, Jeffery PK, Barnes NC: Airway mucosal inflammation in COPD is similar in smokers and ex-smokers: a pooled analysis. Eur Respir J 2007, 30(3):467-471.
• [6]Cosio MG, Saetta M, Agusti A: Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med 2009, 360(23):2445-2454.
• [7]Rennard SI, Calverley PM, Goehring UM, Bredenbroker D, Martinez FJ: Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD. Respir Res 2011, 12(18):18.
• [8]Reid L: Measurements of the bronchial mucous gland layer: a diagnostic yardstick in chronic bronchitis. Thorax 1960, 15:132-141.
• [9]Johnson M, Rennard S: Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD. Chest 2001, 120(1):258-270.
• [10]Doherty MJ, Mister R, Pearson MG, Calverley PM: Capsaicin responsiveness and cough in asthma and chronic obstructive pulmonary disease. Thorax 2000, 55(0040–6376):643-649.
• [11]Blanc FX, Macedo P, Hew M, Chung KF: Capsaicin cough sensitivity in smokers with and without airflow obstruction. Respir Med 2009, 103(5):786-790.
• [12]Fletcher C, Peto R: The natural history of chronic airway obstruction. BMJ 1977, 1:1645-1648.
• [13]Vestbo J, Prescott E, Lange P: Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996, 153(5):1530-1535.
• [14]Probst-Hensch NM, Curjuric I, Pierre-Olivier B, Ckermann-Liebrich U, Bettschart RW, Brandli O, Brutsche M, Burdet L, Gerbase MW, Knöpfli B, Künzli N, Pons MG, Schindler C, Tschopp JM, Rochat T, Russi EW: Longitudinal change of prebronchodilator spirometric obstruction and health outcomes: results from the SAPALDIA cohort. Thorax 2010, 65(2):150-156.
• [15]Kessler R, Partridge MR, Miravitlles M, Cazzola M, Vogelmeier C, Leynaud D, Ostinelli J: Symptom variability in patients with severe COPD: a pan-european cross-sectional study. Eur Respir J 2011, 37(2):264-272.
• [16]Jones PW, Quirk FH, Baveystock CM, Littlejohns P: A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992, 145(6):1321-1327.
• [17]Jones PW, Brusselle G, Dal Negro RW, Ferrer M, Kardos P, Levy ML, Perez T, Soler Cataluña JJ, van der Molen T, Adamek L, Banik N: Properties of the COPD assessment test in a cross-sectional european study. Eur Respir J 2011, 38(1):29-35.
• [18]Chavannes N, Schermer T, Akkermans R, Jacobs JE, van de GG, Bollen R, van Schayck O, Bottema B: Impact of spirometry on GPs' diagnostic differentiation and decision-making. Respir Med 2004, 98(11):1124-1130.
• [19]Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF: Wedzicha JA; evaluation of COPD longitudinally to identify predictive surrogate endpoints (ECLIPSE) investigators, susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010, 363(12):1128-1138.
• [20]Burgel PR, Nesme-Meyer P, Chanez P, Caillaud D, Carre P, Perez T, Roche N: Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 2009, 135(4):975-982.
• [21]Leidy NK, Wilcox TK, Jones PW, Murray L, Winnette R, Howard K, Petrillo J, Powers J, Sethi S: Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): A Patient-Reported Outcome (PRO) Measure. Value Health 2010.
• [22]Kanner RE, Connett JE, Williams DE, Buist AS: Effects of randomized assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in smokers with early chronic obstructive pulmonary disease: the Lung Health Study. Am J Med 1999, 106(4):410-416.
• [23]Smith J, Owen E, Earis J, Woodcock A: Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease. J Allergy Clin Immunol 2006, 117(4):831-835.
• [24]Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C: Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003, 361(9356):449-456.
• [25]Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ: Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009, 374(9691):685-694.